Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Phio Pharmaceuticals Corp
PHIOCurrent price
1.29 USD
-0.06 USD (-4.44%)
Last closed
1.33 USD
Company
www.phiopharma.com
ISIN
US71880W3034
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
2 022 694 USD
Yield for 12 month
-84.90 %
1Y
3Y
5Y
10Y
15Y
PHIO
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts. Address: 11 Apex Drive, Marlborough, MA, United States, 01752
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
36.00 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-6 332 000 USD
Last Year
-193 000 USD
Current Quarter
–
Last Quarter
-1 000 USD
Key Figures PHIO
1 year
3 years
5 years
10 years
EBITDA
-8 567 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-61.07 %
PEG Ratio
–
Return On Equity TTM
-126.86 %
Wall Street Target Price
36.00 USD
Revenue TTM
–
Book Value
7.40 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
-7 012 000 USD
Earnings per share
-14.81 USD
Diluted Eps TTM
-14.81 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics PHIO
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History PHIO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:9
Payout Ratio
–
Last Split Date
05.07.2024
Stock Valuation PHIO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
0.31
Enterprise Value Revenue
172.20
Price Sales TTM
48.01
Enterprise Value EBITDA
0.61
Price Book MRQ
0.61
Financials PHIO
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators PHIO
For 52 weeks
2.17 USD
10.35 USD
50 Day MA
3.07 USD
Shares Short Prior Month
47 983
200 Day MA
5.19 USD
Short Ratio
0.50
Shares Short
48 124
Short Percent
6.00 %
BeatStart